$0.76
4.78%
Nasdaq, Nov 06, 01:22 pm EST. Market open.
ISIN
US1511901050
Symbol
CELU

Celularity Inc - Ordinary Shares - Class A Stock price

$0.73
-0.98 57.58% 1M
-0.23 23.89% 6M
-0.38 34.66% YTD
-1.11 60.58% 1Y
-1.42 66.27% 3Y
-72.17 99.01% 5Y
-97.27 99.26% 10Y
-97.27 99.26% 20Y
Nasdaq, Closing price Thu, Nov 05 2026
-0.08 10.32%
ISIN
US1511901050
Symbol
CELU
Industry

Is Celularity Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,093 stocks worldwide.

Key metrics

Basic
Market capitalization
$23.5m
Enterprise Value
$65.2m
Net debt
$41.6m
Cash
$6.2m
Shares outstanding
28.8m
Valuation
P/E
negative
P/S | estimate
0.9 | 0.5
EV/Sales | estimate
2.5 | 1.5
EV/FCF | ex SBC
negative | negative
P/B
negative
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-230.7%
ROIC
-88.7%
Debt/Equity
-1.3
Share-Based Compensation & Dilution
SBC | % of Revenue
$10.6m | 40.1%
SBC as % of FCF
-
SBC Growth 1Y
-8.0%
Share Count Growth 1Y
27.9%
Shareholder Yield
-27.9%
Financials
Revenue | estimate
$26.6m | $44.9m
EBITDA
$-59.8m
EBIT
$-61.3m
Net Income
$-91.9m
Free Cash Flow | ex SBC
$-13.3m | $-23.9m
Growth
Revenue | estimate
-51.0% | 69.0%
EBITDA
-63.4%
EBIT
-59.8%
Net Income
-59.0%
Free Cash Flow
-64.4%
Margin
Gross
24.4%
EBITDA
-225.3%
EBIT
-230.9%
Net
-346.0%
Free Cash Flow | ex SBC
-49.9% | -90.0%
More
EPS
$-3.2
FCF per Share
$-0.5
Short interest
4.4%
Employees
115
Rev per Employee
$230.0k

Celularity Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:

Buy
86%
Hold
14%

Celularity Inc - Ordinary Shares - Class A Events

Upcoming Event
NOV
12
Q3 2026 Earnings Call
in 6 days
View Past Earnings Reaction

Financial data from Celularity Inc - Ordinary Shares - Class A

Dec '25
+/-
%
27 27
51% 51%
100%
- Direct Costs 20 20
34% 34%
76%
6.48 6.48
83% 83%
24%
- Selling and Administrative Expenses 51 51
13% 13%
193%
- Research and Development Expense 15 15
14% 14%
57%
-60 -60
63% 63%
-225%
- Depreciation and Amortization 1.49 1.49
16% 16%
6%
EBIT (Operating Income) EBIT -61 -61
60% 60%
-231%
Net Profit -92 -92
59% 59%
-346%

In millions USD.

Don't miss a Thing! We will send you all news about Celularity Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celularity Inc - Ordinary Shares - Class A Stock News

Neutral
Business Wire
●
8 days ago
FLORHAM PARK, N.J. & SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and Vesalius Longevity Labs Inc. (“Vesalius”), a leading, global peptide and longevity brand, today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. fina...
Neutral
GlobeNewsWire
●
15 days ago
FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely...
Neutral
GlobeNewsWire
●
about one month ago
Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine
More Celularity Inc - Ordinary Shares - Class A News

Company Profile

Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.

Head office United States
CEO Dr. Hariri
Employees 115
Founded 2016
Website celularity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today